Copyright Reports & Markets. All rights reserved.

Global GLP-1 Agonists for Obesity Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global GLP-1 Agonists for Obesity Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Semaglutide
    • 1.3.3 Tirzepatide
    • 1.3.4 Liraglutide
    • 1.3.5 Benaglutide
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global GLP-1 Agonists for Obesity Consumption Value by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospital Pharmaty
    • 1.4.3 Retail Pharmaty
    • 1.4.4 Others
  • 1.5 Global GLP-1 Agonists for Obesity Market Size & Forecast
    • 1.5.1 Global GLP-1 Agonists for Obesity Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global GLP-1 Agonists for Obesity Sales Quantity (2019-2030)
    • 1.5.3 Global GLP-1 Agonists for Obesity Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Novo Nordisk
    • 2.1.1 Novo Nordisk Details
    • 2.1.2 Novo Nordisk Major Business
    • 2.1.3 Novo Nordisk GLP-1 Agonists for Obesity Product and Services
    • 2.1.4 Novo Nordisk GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Novo Nordisk Recent Developments/Updates
  • 2.2 Eli Lilly
    • 2.2.1 Eli Lilly Details
    • 2.2.2 Eli Lilly Major Business
    • 2.2.3 Eli Lilly GLP-1 Agonists for Obesity Product and Services
    • 2.2.4 Eli Lilly GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Eli Lilly Recent Developments/Updates
  • 2.3 Huadong Medicine
    • 2.3.1 Huadong Medicine Details
    • 2.3.2 Huadong Medicine Major Business
    • 2.3.3 Huadong Medicine GLP-1 Agonists for Obesity Product and Services
    • 2.3.4 Huadong Medicine GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Huadong Medicine Recent Developments/Updates
  • 2.4 Shanghai Benemae Pharmaceutical Corporation
    • 2.4.1 Shanghai Benemae Pharmaceutical Corporation Details
    • 2.4.2 Shanghai Benemae Pharmaceutical Corporation Major Business
    • 2.4.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product and Services
    • 2.4.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates

3 Competitive Environment: GLP-1 Agonists for Obesity by Manufacturer

  • 3.1 Global GLP-1 Agonists for Obesity Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global GLP-1 Agonists for Obesity Revenue by Manufacturer (2019-2024)
  • 3.3 Global GLP-1 Agonists for Obesity Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of GLP-1 Agonists for Obesity by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 GLP-1 Agonists for Obesity Manufacturer Market Share in 2023
    • 3.4.3 Top 6 GLP-1 Agonists for Obesity Manufacturer Market Share in 2023
  • 3.5 GLP-1 Agonists for Obesity Market: Overall Company Footprint Analysis
    • 3.5.1 GLP-1 Agonists for Obesity Market: Region Footprint
    • 3.5.2 GLP-1 Agonists for Obesity Market: Company Product Type Footprint
    • 3.5.3 GLP-1 Agonists for Obesity Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global GLP-1 Agonists for Obesity Market Size by Region
    • 4.1.1 Global GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2030)
    • 4.1.2 Global GLP-1 Agonists for Obesity Consumption Value by Region (2019-2030)
    • 4.1.3 Global GLP-1 Agonists for Obesity Average Price by Region (2019-2030)
  • 4.2 North America GLP-1 Agonists for Obesity Consumption Value (2019-2030)
  • 4.3 Europe GLP-1 Agonists for Obesity Consumption Value (2019-2030)
  • 4.4 Asia-Pacific GLP-1 Agonists for Obesity Consumption Value (2019-2030)
  • 4.5 South America GLP-1 Agonists for Obesity Consumption Value (2019-2030)
  • 4.6 Middle East & Africa GLP-1 Agonists for Obesity Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
  • 5.2 Global GLP-1 Agonists for Obesity Consumption Value by Type (2019-2030)
  • 5.3 Global GLP-1 Agonists for Obesity Average Price by Type (2019-2030)

6 Market Segment by Application

  • 6.1 Global GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
  • 6.2 Global GLP-1 Agonists for Obesity Consumption Value by Application (2019-2030)
  • 6.3 Global GLP-1 Agonists for Obesity Average Price by Application (2019-2030)

7 North America

  • 7.1 North America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
  • 7.2 North America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
  • 7.3 North America GLP-1 Agonists for Obesity Market Size by Country
    • 7.3.1 North America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
    • 7.3.2 North America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
  • 8.2 Europe GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
  • 8.3 Europe GLP-1 Agonists for Obesity Market Size by Country
    • 8.3.1 Europe GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
  • 9.3 Asia-Pacific GLP-1 Agonists for Obesity Market Size by Region
    • 9.3.1 Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific GLP-1 Agonists for Obesity Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 South Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
  • 10.2 South America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
  • 10.3 South America GLP-1 Agonists for Obesity Market Size by Country
    • 10.3.1 South America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
    • 10.3.2 South America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
  • 11.3 Middle East & Africa GLP-1 Agonists for Obesity Market Size by Country
    • 11.3.1 Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 GLP-1 Agonists for Obesity Market Drivers
  • 12.2 GLP-1 Agonists for Obesity Market Restraints
  • 12.3 GLP-1 Agonists for Obesity Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of GLP-1 Agonists for Obesity and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of GLP-1 Agonists for Obesity
  • 13.3 GLP-1 Agonists for Obesity Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 GLP-1 Agonists for Obesity Typical Distributors
  • 14.3 GLP-1 Agonists for Obesity Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists have been approved to help treat obesity. GLP-1 agonists have been shown to be effective in promoting weight loss in preclinical and clinical studies.
    According to our (Global Info Research) latest study, the global GLP-1 Agonists for Obesity market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global GLP-1 Agonists for Obesity market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
    Key Features:
    Global GLP-1 Agonists for Obesity market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
    Global GLP-1 Agonists for Obesity market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
    Global GLP-1 Agonists for Obesity market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
    Global GLP-1 Agonists for Obesity market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2019-2024
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for GLP-1 Agonists for Obesity
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global GLP-1 Agonists for Obesity market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    GLP-1 Agonists for Obesity market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Semaglutide
    Tirzepatide
    Liraglutide
    Benaglutide
    Market segment by Application
    Hospital Pharmaty
    Retail Pharmaty
    Others
    Major players covered
    Novo Nordisk
    Eli Lilly
    Huadong Medicine
    Shanghai Benemae Pharmaceutical Corporation
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe GLP-1 Agonists for Obesity product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of GLP-1 Agonists for Obesity, with price, sales quantity, revenue, and global market share of GLP-1 Agonists for Obesity from 2019 to 2024.
    Chapter 3, the GLP-1 Agonists for Obesity competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the GLP-1 Agonists for Obesity breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and GLP-1 Agonists for Obesity market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1 Agonists for Obesity.
    Chapter 14 and 15, to describe GLP-1 Agonists for Obesity sales channel, distributors, customers, research findings and conclusion.

    Buy now